Welcome to our dedicated page for OMADA HEALTH SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. reported that Chief Executive Officer Sean P. Duffy received a grant of 323,529 restricted stock units (RSUs) of Common Stock at no cash cost. Each RSU converts into one share upon vesting. One-sixteenth of the RSUs vest on each quarterly anniversary beginning March 1, 2026, so the award fully vests on the fourth anniversary of that date.
After this grant, Duffy beneficially owns 441,127 shares directly. An additional 861,109 shares are held indirectly in family trusts for the benefit of his family members, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
Omada Health, Inc. Chief Executive Officer Sean P. Duffy reported open-market sales of a total of 4,063 shares of common stock on March 9, 2026. The transactions consisted of 3,863 shares sold at a weighted average price of $14.3151 per share and 200 shares sold at a weighted average price of $14.8850 per share.
According to the filing, these sales were made pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2025, indicating they were pre-scheduled. After these sales, Duffy held 117,598 shares directly. He also had 861,109 shares held indirectly in family trusts for the benefit of his family members, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Omada Health, Inc. President Shao Wei-Li reported a tax-related share disposition under an insider Form 4. On March 5, 2026, 2,105 shares of common stock were disposed of at $13.60 per share to cover tax withholding obligations, a non-open-market transaction. After this tax-withholding disposition, Shao Wei-Li directly owned 66,974 shares of Omada Health common stock.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported a tax-withholding disposition of 2,228 shares of common stock at $13.60 per share on March 5, 2026. After this non-open-market transaction to cover tax obligations, he directly owns 55,338 shares of Omada Health common stock.
Omada Health, Inc. Chief Executive Officer Sean P. Duffy reported a tax-related share disposition. On March 5, 2026, he disposed of 4,983 shares of common stock at $13.60 per share in a transaction coded as a tax-withholding disposition, leaving 121,661 shares held directly.
He also reports 861,109 shares of common stock held indirectly through family trusts noted in a footnote. These trusts hold shares for the benefit of his family members, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
Morgan Stanley Smith Barney LLC reports 10b5-1 sales of OMDA common stock by Sean Duffy. The filing lists three sales: 01/12/2026 of 230,479 shares for $3,595,149.73, 01/13/2026 of 40,796 shares for $650,773.71, and 12/10/2025 of 9,266 shares for $142,378.58.
Omada Health, Inc. outlines its virtual chronic-care business, pairing human coaches and clinicians with AI-enabled tools to manage cardiometabolic and musculoskeletal conditions for employers, health plans, PBMs, and health systems.
As of December 31, 2025, Omada reports over 2,000 customers, more than 886,000 enrolled members, and nearly two million members served since launch. Over 55% of cardiometabolic members remained engaged at month 12 and over 50% at month 24, supporting its outcomes-focused model.
The company is expanding GLP-1–related offerings, including an Enhanced GLP-1 Care Track and planned prescribing capability, and cites internal data showing 16.3% average weight loss for persistently engaged GLP-1 users. Omada also discloses continued net losses of $12.8 million, $47.1 million, and $67.5 million for 2025, 2024, and 2023, with an accumulated deficit of $456.7 million, while emphasizing more than 90% three-year customer retention and high satisfaction scores.
Omada Health, Inc. reported rapid growth and a key profitability milestone for 2025. Total members reached 886,000 at year end, up 55% year over year, reflecting strong demand for its virtual chronic care programs.
Revenue was $76 million in the fourth quarter, up 58% year over year, and $260 million for the full year, up 53% compared with 2024. Gross margin improved to 71% in the fourth quarter and 66% for the year, indicating better unit economics. The company generated net income of $5 million in the fourth quarter versus a net loss a year earlier, and narrowed its full‑year net loss to $13 million from $47 million. Adjusted EBITDA turned positive at $8 million in the fourth quarter and $6 million for the year.
Cash and cash equivalents were $222 million as of December 31, 2025, supported by IPO proceeds and debt repayment, leaving no long‑term debt. For 2026, Omada expects revenue between $312 million and $322 million and adjusted EBITDA between $7 million and $15 million, implying continued growth with maintained profitability on an adjusted basis.
Omada Health, Inc. ownership was reported by Divisadero Street-affiliated filers showing shared beneficial ownership of 5,056,517 common shares representing 8.7% of the class and affiliated entities holding 3,656,064 shares representing 6.3%.
The filing states these securities are directly owned by advisory clients of Divisadero Street Capital Management, LP, and includes a disclaimer that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The schedule is signed by William Zolezzi.